Loading clinical trials...

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma

NCT02004262•Aduro Biotech, Inc.

View on ClinicalTrials.gov

Summary

Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have histologically proven malignant adenocarcinoma of the pancreas; measurable disease is not required, mixed histology is not allowed; subjects must have metastatic disease
•2nd line, 3rd line or greater
•At least 18 years of age
•Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
•Anticipated life expectancy \>12 weeks
•For women and men of childbearing potential, a medically acceptable method of highly effective contraception (oral hormonal contraceptive, condom plus spermicide, or hormone implants) must be used throughout the study period and for 28 days after their final vaccine administration. A barrier method of contraception must be employed by all subjects (male and female), regardless of other methods.
•Have adequate organ function as defined by specified laboratory values

Exclusion Criteria

•Allergy to both penicillin \& sulfa or suspected hypersensitivity to granulocyte-macrophage colony stimulating factor (GM-CSF), dimethyl sulfoxide, fetal bovine serum, trypsin, yeast, glycerol or other component of the therapy options
•Known history or evidence of brain metastases, immunodeficiency disease or immunocompromised state or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment
•Have any evidence of hepatic cirrhosis or clinical or radiographic ascites
•Have prosthetic heart valves, major implant or device placed in the last 12 months or history of infection with implant/device that cannot be easily removed
•Rapidly progressing disease
•Clinically significant and/or malignant pleural effusion
•Received prior GVAX pancreas vaccine or CRS-207
•Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
•Infection with HIV or hepatitis B or C at screening
•Valvular heart disease that requires antibiotic prophylaxis for prevention of endocarditis
+3 more criteria

Locations (21)

Scottsdale Healthcare Research Institute

Scottsdale, Arizona, United States

University California San Diego Moores Cancer Center

La Jolla, California, United States

University of California Mt Zion Comprehensive Cancer Center

San Francisco, California, United States

University of California Los Angeles

Santa Monica, California, United States

University of Colorado Denver

Aurora, Colorado, United States

University of Miami/Sylvester Cancer Center

Miami, Florida, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Johns Hopkins University

Baltimore, Maryland, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Washington University

St Louis, Missouri, United States

Key Dates

Start Date

February 5, 2014

Primary Completion Date

January 1, 2016

Completion Date

August 23, 2016

Last Updated

June 4, 2018

Enrollment

303

ACTUAL participants

Conditions

2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer

Interventions

GVAX Pancreas Vaccine

BIOLOGICAL

CRS-207

BIOLOGICAL

Chemotherapy

DRUG

cyclophosphamide

DRUG